SK Bioscience Co Ltd (KO:302440) — Market Cap & Net Worth
Market Cap & Net Worth: SK Bioscience Co Ltd (302440)
SK Bioscience Co Ltd (KO:302440) has a market capitalization of $1.95 Billion (₩2.88 Trillion) as of September 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #6250 globally and #149 in its home market, demonstrating a -2.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SK Bioscience Co Ltd's stock price ₩36750.00 by its total outstanding shares 78434701 (78.43 Million). Also see 302440 total assets for a full breakdown of the balance sheet.
SK Bioscience Co Ltd Market Cap History: 2021 to 2026
SK Bioscience Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $11.96 Billion to $1.95 Billion (-24.23% CAGR). Also see SK Bioscience Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
SK Bioscience Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SK Bioscience Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SK Bioscience Co Ltd share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
SK Bioscience Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $11.96 Billion | $929.00 Billion | $355.14 Billion | 0.01x | 0.03x |
| 2022 | $3.91 Billion | $456.73 Billion | $122.45 Billion | 0.01x | 0.03x |
| 2023 | $3.83 Billion | $369.51 Billion | $22.32 Billion | 0.01x | 0.17x |
| 2024 | $2.68 Billion | $267.55 Billion | -$53.88 Billion | 0.01x | N/A |
Competitor Companies of 302440 by Market Capitalization
Companies near SK Bioscience Co Ltd in the global market cap rankings as of September 17, 2026. Review 302440 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to SK Bioscience Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
SK Bioscience Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, SK Bioscience Co Ltd's market cap moved from $11.96 Billion to $ 1.95 Billion, with a yearly change of -24.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩1.95 Billion | -23.76% |
| 2025 | ₩2.56 Billion | -4.37% |
| 2024 | ₩2.68 Billion | -30.00% |
| 2023 | ₩3.83 Billion | -2.04% |
| 2022 | ₩3.91 Billion | -67.33% |
| 2021 | ₩11.96 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of SK Bioscience Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Billion USD |
| MoneyControl | $1.95 Billion USD |
| MarketWatch | $1.95 Billion USD |
| marketcap.company | $1.95 Billion USD |
| Reuters | $1.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SK Bioscience Co Ltd
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the preve… Read more